Uncategorized
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the fourth quarter and full year ended December 31, 2018. Key Highlights: Launched INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% in January 2019 for the treatment of post-operative